CORRECTION article

Front. Immunol., 24 July 2025

Sec. Multiple Sclerosis and Neuroimmunology

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1652299

Correction: The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm

  • 1. Department of Neurology, St. Josef-Hospital, Bochum, Germany

  • 2. Translational Neurology Group, Department of Clinical Science, Lund University, Lund, Sweden

  • 3. Molecular Cell Biology, Ruhr-University, Bochum, Germany

  • 4. Affectis Pharmaceuticals AG, Dortmund, Germany

  • 5. KHAN Technology Transfer Fund I GmbH & Co KG, Dortmund, Germany

  • 6. Lead Discovery Center GmbH, Dortmund, Germany

  • 7. Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Germany

Author “Steffen Haupeltshofer” was omitted as an author in the published article. The correct author list reads:

“Robert Hoffrogge1, Anna Karachunskaya1, Neele Heitmann1, Steffen Haupeltshofer2, Xiomara Pedreiturria1, Katharina Klöster1, Verian Bader3, Konstanze F. Winklhofer3, Michael Hamacher4, Bert Klebl5, Ralf Gold1, Klaus Dinkel6, Ingo Kleiter1,7, Simon Faissner1*

1Department of Neurology, St. Josef-Hospital, Bochum, Germany

2Translational Neurology Group, Department of Clinical Science, Lund University, Lund, Sweden

3Molecular Cell Biology, Ruhr-University, Bochum, Germany

4Affectis Pharmaceuticals AG, Dortmund, Germany

5KHAN Technology Transfer Fund I GmbH & Co KG, Dortmund, Germany

6Lead Discovery Center GmbH, Dortmund, Germany

7Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Germany”

The Author contributions statement has been corrected to read:

“RH: Writing – original draft, Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Visualization. AK: Writing – review & editing, Formal Analysis, Investigation, Methodology, Visualization. NH: Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization. SH: Writing – original draft, Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization.XP: Writing – review & editing, Formal Analysis, Investigation, Methodology, Project administration, Resources, Validation. KK: Writing – review & editing, Data curation, Formal Analysis, Investigation, Methodology. VB: Writing – review & editing, Formal Analysis, Investigation, Methodology, Software, Visualization. KW: Writing – review & editing, Formal Analysis, Methodology, Resources, Software. MH: Writing – review & editing, Resources. BK: Writing – review & editing, Resources. RG: Writing – review & editing, Funding acquisition, Resources. KD: Writing – review & editing, Resources. IK: Writing – review & editing, Conceptualization, Formal Analysis, Funding acquisition, Supervision, Visualization. SF: Writing – original draft, Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Visualization.”

The original version of this article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

P2X7R, progressive multiple sclerosis, microglia, neuroinflammation, neuroprotection

Citation

Hoffrogge R, Karachunskaya A, Heitmann N, Haupeltshofer S, Pedreiturria X, Klöster K, Bader V, Winklhofer KF, Hamacher M, Klebl B, Gold R, Dinkel K, Kleiter I and Faissner S (2025) Correction: The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm. Front. Immunol. 16:1652299. doi: 10.3389/fimmu.2025.1652299

Received

23 June 2025

Accepted

09 July 2025

Published

24 July 2025

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

16 - 2025

Updates

Copyright

*Correspondence: Simon Faissner,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics